| ［1］ |
Bigliardi PL, Dancik Y, Neumann C, et al. Opioids and skin homeostasis, regeneration and ageing ⁃What′s the evidence?［J］. Exp Dermatol, 2016,25（8）:586⁃591. doi: 10.1111/exd.13021.
|
| ［2］ |
Wang X, Zhang Y, Peng Y, et al. Pharmacological characteri⁃zation of the opioid inactive isomers（+）⁃naltrexone and （+）⁃naloxone as antagonists of toll⁃like receptor 4［J］. Br J Pharmacol, 2016,173（5）:856⁃869. doi: 10.1111/bph.13394.
|
| ［3］ |
Trofimovitch D, Baumrucker SJ. Pharmacology update: low⁃dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes［J］. Am J Hosp Palliat Care, 2019,36（10）:907⁃912. doi: 10.1177/1049909119838974.
|
| ［4］ |
Younger J, Parkitny L, McLain D. The use of low⁃dose naltrexone （LDN） as a novel anti⁃inflammatory treatment for chronic pain［J］. Clin Rheumatol, 2014,33（4）:451⁃459. doi: 10.1007/s10067⁃014⁃2517⁃2.
|
| ［5］ |
Albers LN, Arbiser JL, Feldman RJ. Treatment of Hailey⁃Hailey disease with low⁃dose naltrexone［J］. JAMA Dermatol, 2017,153（10）:1018⁃1020. doi: 10.1001/jamadermatol.2017.2446.
|
| ［6］ |
Riquelme⁃Mc Loughlin C, Riera⁃Monroig J, Morgado⁃Carrasco D, et al. Low⁃dose naltrexone therapy in benign chronic pemphigus （Hailey⁃Hailey disease）: a case series［J］. J Am Acad Dermatol, 2019,81（2）:644⁃646. doi: 10.1016/j.jaad.2019.04.024.
|
| ［7］ |
Cao S, Lilly E, Chen ST. Variable response to naltrexone in patients with Hailey⁃Hailey disease［J］. JAMA Dermatol, 2018,154（3）:362⁃363. doi: 10.1001/jamadermatol.2017.5463.
|
